Prelude Therapeutics
PRLD
55 hedge funds and large institutions have $176M invested in Prelude Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 14 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
14.65% more ownership
Funds ownership: 65.72% → 80.37% (+15%)
2% more funds holding
Funds holding: 54 → 55 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
2% less capital invested
Capital invested by funds: $180M → $176M (-$3.42M)
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$10.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.33M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.92M |
| 4 |
O
OrbiMed
New York
|
+$5.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$739K |
| 2 |
Citigroup
New York
|
-$400K |
| 3 |
Jane Street
New York
|
-$367K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$173K |
| 5 |
6CM
683 Capital Management
New York
|
-$163K |
PRLD Hedge Fund Activity: Q2 2023 in Review
55 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2023, worth a combined $176M — down 1.9% from $180M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PRLD positions and 14 closed out — a net gain of 1 holder — while 25 added to existing stakes and 9 trimmed.
The largest buyer was Boxer Capital, adding an estimated $10.7M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $739K sold.
- 55 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2023, up from 54 in Q1 2023.
- Funds reported $176M of Prelude Therapeutics stock for Q2 2023, down 1.9% quarter-over-quarter.
- 15 funds opened new Prelude Therapeutics positions in Q2 2023 and 14 closed out, a net change of +1 holder.
- The largest Prelude Therapeutics buyer in Q2 2023 was Boxer Capital, an estimated $10.7M added.
- The largest Prelude Therapeutics seller in Q2 2023 was Susquehanna International Group, an estimated $739K sold.
Based on aggregated 13F filings for Q2 2023.